1. Update on Pharmacologic Management of OA
Summary: Efficacy
1Bingham B et al. Nature Clinical Practice Rheumatology (2009) 5, 28-37 Provided by: Thomas J. Schnitzer MD, PhDProvided by: Thomas J. Schnitzer MD, PhDProvided by: Thomas J. Schnitzer MD, PhDProvided by: Thomas J. Schnitzer MD, PhDProvided by: Thomas J. Schnitzer MD, PhD
2. • Anti-NGF mAbs to continue to be developed
• Efficacy superior to NSAIDs/opioids
• Safety to be better defined
• Define population with acceptable benefit:risk profile
• Centrally acting compounds will continue to be sought
• Supra-spinal pathways in pain addressed
Update on Pharmacologic Management of OA
Summary: Efficacy
Provided by: Thomas J. Schnitzer MD, PhD
Editor's Notes
First new drug for MS pain in over 100 years and with the potential to treat neuropathic and visceral pain conditions, clinical entities for which we do not currently have effective therapiesThe decisions today are whether to allow research to continue – not to approve these drugs for marketing and general use; additional research can be directed not only to new clinical indications but also to a fuller appreciation of safety
